FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094239421> ?p ?o ?g. }

• W2094239421 endingPage "S525" @default.
• W2094239421 startingPage "S525" @default.
• W2094239421 abstract "Purpose/Objective(s)The most common primary tumor for patients with brain metastases (BM) is lung cancer. For patients with stage III NSCLC, first site of recurrence is brain in up to 40% of cases. Prophylactic cranial irradiation reduces incidence of brain failure, but can lead to neurocognitive deficits. We evaluated variables potentially related to brain relapse (BR) and survival to better select patients for brain treatment.Materials/MethodsBetween 2000 and 2010, 212 patients were diagnosed with pathologically confirmed stage III-IV NSCLC at Northwestern. Primary endpoint was BR, and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Cox regression univariate analyses were performed.ResultsIn patients without BM at initial NSCLC diagnosis, adenosquamous (AS) type and lower KPS at initial diagnosis were associated with eventual BR (see Table). After diagnosis with BM, higher stage, higher grade, AS type, lesser extent of lung or brain resection, lower brain RT dose were associated with further BR within 1 year, while less smoking pack-years, AS and adenocarcinoma (adeno) types, higher grade, higher initial lung primary SUV, lesser lung and brain resection, and omission of anti-EGFR therapies were associated with development of and shorter time to further BR. Higher KPS, less smoking pack-years, lower stage, lower grade, adeno type, greater extent of lung resection, treatment with chemotherapy, more chemotherapy cycles, higher lung radiation (RT) dose were associated with improved PFS, while higher KPS, less smoking pack-years, lower stage, AS and adeno types, greater extent of lung or brain resection, treatment with chemotherapy, more chemotherapy cycles, higher lung RT dose were associated with improved OS.ConclusionsPoster Viewing Abstract 2844; TableEndpointCompared groupsHazard ratioP value95% Confidence intervalBR in patients without initial BMAS vs adeno3.987.0021.646-9.657BR in patients without initial BMInitial KPS = 702.781.0560.973-7.949Further BR within 1 year after initial BMAS vs adeno4.481.0101.340-14.986Further BR within 1 year after initial BMAS vs squamous cell carcinoma (SCC)10.416.0022.415-45.4542 or more brain failuresAS vs adeno3.279.0530.984-10.9332 or more brain failuresAS vs SCC3.174.0021.230-8.196SurvivalAS vs SCC3.552.0041.469-8.587 Open table in a new tab Purpose/Objective(s)The most common primary tumor for patients with brain metastases (BM) is lung cancer. For patients with stage III NSCLC, first site of recurrence is brain in up to 40% of cases. Prophylactic cranial irradiation reduces incidence of brain failure, but can lead to neurocognitive deficits. We evaluated variables potentially related to brain relapse (BR) and survival to better select patients for brain treatment. The most common primary tumor for patients with brain metastases (BM) is lung cancer. For patients with stage III NSCLC, first site of recurrence is brain in up to 40% of cases. Prophylactic cranial irradiation reduces incidence of brain failure, but can lead to neurocognitive deficits. We evaluated variables potentially related to brain relapse (BR) and survival to better select patients for brain treatment. Materials/MethodsBetween 2000 and 2010, 212 patients were diagnosed with pathologically confirmed stage III-IV NSCLC at Northwestern. Primary endpoint was BR, and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Cox regression univariate analyses were performed. Between 2000 and 2010, 212 patients were diagnosed with pathologically confirmed stage III-IV NSCLC at Northwestern. Primary endpoint was BR, and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Cox regression univariate analyses were performed. ResultsIn patients without BM at initial NSCLC diagnosis, adenosquamous (AS) type and lower KPS at initial diagnosis were associated with eventual BR (see Table). After diagnosis with BM, higher stage, higher grade, AS type, lesser extent of lung or brain resection, lower brain RT dose were associated with further BR within 1 year, while less smoking pack-years, AS and adenocarcinoma (adeno) types, higher grade, higher initial lung primary SUV, lesser lung and brain resection, and omission of anti-EGFR therapies were associated with development of and shorter time to further BR. Higher KPS, less smoking pack-years, lower stage, lower grade, adeno type, greater extent of lung resection, treatment with chemotherapy, more chemotherapy cycles, higher lung radiation (RT) dose were associated with improved PFS, while higher KPS, less smoking pack-years, lower stage, AS and adeno types, greater extent of lung or brain resection, treatment with chemotherapy, more chemotherapy cycles, higher lung RT dose were associated with improved OS. In patients without BM at initial NSCLC diagnosis, adenosquamous (AS) type and lower KPS at initial diagnosis were associated with eventual BR (see Table). After diagnosis with BM, higher stage, higher grade, AS type, lesser extent of lung or brain resection, lower brain RT dose were associated with further BR within 1 year, while less smoking pack-years, AS and adenocarcinoma (adeno) types, higher grade, higher initial lung primary SUV, lesser lung and brain resection, and omission of anti-EGFR therapies were associated with development of and shorter time to further BR. Higher KPS, less smoking pack-years, lower stage, lower grade, adeno type, greater extent of lung resection, treatment with chemotherapy, more chemotherapy cycles, higher lung radiation (RT) dose were associated with improved PFS, while higher KPS, less smoking pack-years, lower stage, AS and adeno types, greater extent of lung or brain resection, treatment with chemotherapy, more chemotherapy cycles, higher lung RT dose were associated with improved OS. ConclusionsPoster Viewing Abstract 2844; TableEndpointCompared groupsHazard ratioP value95% Confidence intervalBR in patients without initial BMAS vs adeno3.987.0021.646-9.657BR in patients without initial BMInitial KPS = 702.781.0560.973-7.949Further BR within 1 year after initial BMAS vs adeno4.481.0101.340-14.986Further BR within 1 year after initial BMAS vs squamous cell carcinoma (SCC)10.416.0022.415-45.4542 or more brain failuresAS vs adeno3.279.0530.984-10.9332 or more brain failuresAS vs SCC3.174.0021.230-8.196SurvivalAS vs SCC3.552.0041.469-8.587 Open table in a new tab" @default.
• W2094239421 created "2016-06-24" @default.
• W2094239421 creator A5001271558 @default.
• W2094239421 creator A5003314572 @default.
• W2094239421 creator A5003803483 @default.
• W2094239421 creator A5038585908 @default.
• W2094239421 creator A5039680305 @default.
• W2094239421 creator A5053878729 @default.
• W2094239421 creator A5060733211 @default.
• W2094239421 creator A5069781107 @default.
• W2094239421 creator A5073206138 @default.
• W2094239421 creator A5077814055 @default.
• W2094239421 date "2013-10-01" @default.
• W2094239421 modified "2023-10-16" @default.
• W2094239421 title "Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer (NSCLC)" @default.
• W2094239421 doi "https://doi.org/10.1016/j.ijrobp.2013.06.1388" @default.
• W2094239421 hasPublicationYear "2013" @default.
• W2094239421 type Work @default.
• W2094239421 sameAs 2094239421 @default.
• W2094239421 citedByCount "1" @default.
• W2094239421 countsByYear W20942394212014 @default.
• W2094239421 crossrefType "journal-article" @default.
• W2094239421 hasAuthorship W2094239421A5001271558 @default.
• W2094239421 hasAuthorship W2094239421A5003314572 @default.
• W2094239421 hasAuthorship W2094239421A5003803483 @default.
• W2094239421 hasAuthorship W2094239421A5038585908 @default.
• W2094239421 hasAuthorship W2094239421A5039680305 @default.
• W2094239421 hasAuthorship W2094239421A5053878729 @default.
• W2094239421 hasAuthorship W2094239421A5060733211 @default.
• W2094239421 hasAuthorship W2094239421A5069781107 @default.
• W2094239421 hasAuthorship W2094239421A5073206138 @default.
• W2094239421 hasAuthorship W2094239421A5077814055 @default.
• W2094239421 hasConcept C121608353 @default.
• W2094239421 hasConcept C126322002 @default.
• W2094239421 hasConcept C143998085 @default.
• W2094239421 hasConcept C144301174 @default.
• W2094239421 hasConcept C146357865 @default.
• W2094239421 hasConcept C151730666 @default.
• W2094239421 hasConcept C203092338 @default.
• W2094239421 hasConcept C2776256026 @default.
• W2094239421 hasConcept C2776512503 @default.
• W2094239421 hasConcept C2776694085 @default.
• W2094239421 hasConcept C2776907518 @default.
• W2094239421 hasConcept C2778164965 @default.
• W2094239421 hasConcept C2779013556 @default.
• W2094239421 hasConcept C2781182431 @default.
• W2094239421 hasConcept C38180746 @default.
• W2094239421 hasConcept C509974204 @default.
• W2094239421 hasConcept C535046627 @default.
• W2094239421 hasConcept C71924100 @default.
• W2094239421 hasConcept C86803240 @default.
• W2094239421 hasConceptScore W2094239421C121608353 @default.
• W2094239421 hasConceptScore W2094239421C126322002 @default.
• W2094239421 hasConceptScore W2094239421C143998085 @default.
• W2094239421 hasConceptScore W2094239421C144301174 @default.
• W2094239421 hasConceptScore W2094239421C146357865 @default.
• W2094239421 hasConceptScore W2094239421C151730666 @default.
• W2094239421 hasConceptScore W2094239421C203092338 @default.
• W2094239421 hasConceptScore W2094239421C2776256026 @default.
• W2094239421 hasConceptScore W2094239421C2776512503 @default.
• W2094239421 hasConceptScore W2094239421C2776694085 @default.
• W2094239421 hasConceptScore W2094239421C2776907518 @default.
• W2094239421 hasConceptScore W2094239421C2778164965 @default.
• W2094239421 hasConceptScore W2094239421C2779013556 @default.
• W2094239421 hasConceptScore W2094239421C2781182431 @default.
• W2094239421 hasConceptScore W2094239421C38180746 @default.
• W2094239421 hasConceptScore W2094239421C509974204 @default.
• W2094239421 hasConceptScore W2094239421C535046627 @default.
• W2094239421 hasConceptScore W2094239421C71924100 @default.
• W2094239421 hasConceptScore W2094239421C86803240 @default.
• W2094239421 hasIssue "2" @default.
• W2094239421 hasLocation W20942394211 @default.
• W2094239421 hasOpenAccess W2094239421 @default.
• W2094239421 hasPrimaryLocation W20942394211 @default.
• W2094239421 hasRelatedWork W1602357875 @default.
• W2094239421 hasRelatedWork W1831765636 @default.
• W2094239421 hasRelatedWork W2221629589 @default.
• W2094239421 hasRelatedWork W2234839489 @default.
• W2094239421 hasRelatedWork W2277416945 @default.
• W2094239421 hasRelatedWork W2360529269 @default.
• W2094239421 hasRelatedWork W2380658010 @default.
• W2094239421 hasRelatedWork W2743740828 @default.
• W2094239421 hasRelatedWork W2888534976 @default.
• W2094239421 hasRelatedWork W3031381806 @default.
• W2094239421 hasVolume "87" @default.
• W2094239421 isParatext "false" @default.
• W2094239421 isRetracted "false" @default.
• W2094239421 magId "2094239421" @default.
• W2094239421 workType "article" @default.